Literature DB >> 17440024

Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.

A Hróbjartsson1, E Forfang, M T Haahr, B Als-Nielsen, S Brorson.   

Abstract

BACKGROUND: Blinding can reduce bias in randomized clinical trials, but blinding procedures may be unsuccessful. Our aim was to assess how often randomized clinical trials test the success of blinding, the methods involved and how often blinding is reported as being successful.
METHODS: We analysed a random sample of blinded randomized clinical trials indexed in the The Cochrane Central Register of Controlled Trials and published in 2001. We identified 1599 blinded trials, and noted if they had conducted any test for the success of blinding. We also selected 200 trials randomly that did not report any such test, and sent a questionnaire to the corresponding authors asking them if they had conducted any tests.
RESULTS: Thirty-one out of 1599 trials (2%) reported tests for the success of blinding. Test methods varied, and reporting was generally incomplete. Blinding was considered successful in 14 out of the 31 trials (45%) and unclear in 10 (32%). Of the seven trials (23%) reporting unsuccessful blinding the risk of a biased trial result was either not addressed or was discounted in six cases. We received 130 questionnaires from trial authors (65%) of which 15 (12%) informed that they had conducted, but not published, tests.
CONCLUSIONS: Blinding is rarely tested. Test methods vary, and the reporting of tests, and test results, is incomplete. There is a considerable methodological uncertainty how best to assess blinding, and an urgent need for improved methodology and improved reporting.

Mesh:

Year:  2007        PMID: 17440024     DOI: 10.1093/ije/dym020

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  46 in total

1.  How to read a clinical trial paper: a lesson in basic trial statistics.

Authors:  Shail M Govani; Peter D R Higgins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-04

2.  The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?

Authors:  Jeremy Howick; Paul Glasziou; Jeffrey K Aronson
Journal:  J R Soc Med       Date:  2009-05       Impact factor: 5.344

Review 3.  Assessing blinding in randomised controlled trials of acupuncture: challenges and recommendations.

Authors:  Ann K Hopton; Hugh Macpherson
Journal:  Chin J Integr Med       Date:  2011-02-27       Impact factor: 1.978

4.  Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis.

Authors:  Ben Colagiuri; Robert A Boakes
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

5.  Placebo orthodoxy and the double standard of care in multinational clinical research.

Authors:  Maya J Goldenberg
Journal:  Theor Med Bioeth       Date:  2015-02

6.  Issues of design and statistical analysis in controlled clinical acupuncture trials: an analysis of English-language reports from Western journals.

Authors:  Ping Shuai; Xiao-Hua Zhou; Lixing Lao; Xiaosong Li
Journal:  Stat Med       Date:  2011-02-22       Impact factor: 2.373

7.  The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry.

Authors:  Changsu Han; Kyung-phil Kwak; David M Marks; Chi-Un Pae; Li-Tzy Wu; Kamal S Bhatia; Prakash S Masand; Ashwin A Patkar
Journal:  Contemp Clin Trials       Date:  2008-11-30       Impact factor: 2.226

Review 8.  Assessing blinding in trials of psychiatric disorders: a meta-analysis based on blinding index.

Authors:  Brian Freed; Oliver Paul Assall; Gary Panagiotakis; Heejung Bang; Jongbae J Park; Alex Moroz; Christopher Baethge
Journal:  Psychiatry Res       Date:  2014-05-22       Impact factor: 3.222

9.  Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study.

Authors:  Vicki Hertzberg; Marc Chimowitz; Michael Lynn; Cristen Chester; William Asbury; George Cotsonis
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

10.  Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups? A protocol for a meta-epidemiological study of PDE-5 inhibitors.

Authors:  Frederik Feys; Geertruida E Bekkering; Kavita Singh; Dirk Devroey
Journal:  Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.